A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05002127 |
|
Recruitment Status :
Recruiting
First Posted : August 12, 2021
Last Update Posted : January 25, 2023
|
Sponsor:
ALX Oncology Inc.
Collaborator:
Eli Lilly and Company
Information provided by (Responsible Party):
ALX Oncology Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | July 2026 |
| Estimated Study Completion Date : | August 2028 |